You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The two firms aim to bring down costs and turnaround time with two newly-launched sequencing tests for respiratory pathogens, RVOP 2 and Explify RPIP.
Qiagen received CE IVD marking for its NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test and for a saliva collection kit for its single-plex NeuMoDx SARS-CoV-2 assay.
The firm beat the consensus Wall Street estimate on the top line but fell short of the estimate on the bottom line.
The test is designed to measure the expression of IFI27, a gene strongly correlated with disease progression in influenza and COVID-19.
The company's system revenues were up 28 percent to $19.5 million and consumables revenues dropped 12 percent to $11.8 million.
The company recently received FDA Emergency Use Authorization for its SARS-CoV-2 PCR test while its data-driven COVID-19 research initiative is moving along.
The company said its clinical lab revenues rose nearly 5 percent, but revenues from its life sciences business fell 26 percent because of the COVID-19 pandemic.
The company said that the FDA has granted it Emergency Use Authorization for a respiratory panel that includes SARS-CoV-2, flu, and other pathogens.
BioFire's test is designed to detect and differentiate between SARS-CoV-2 and other respiratory pathogens, while UMass Medical's test is only for SARS-CoV-2.
The extended molecular panel combines SARS-CoV-2 with other common respiratory pathogen targets. It includes 19 viral and two bacterial targets.